BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 17154521)

  • 1. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers.
    Aronov AM
    J Med Chem; 2006 Nov; 49(23):6917-21. PubMed ID: 17154521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
    Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
    J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive QSAR models development and validation for human ether-a-go-go related gene (hERG) blockers using newer tools.
    Moorthy NS; Ramos MJ; Fernandes PA
    J Enzyme Inhib Med Chem; 2014 Jun; 29(3):317-24. PubMed ID: 23560722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel hypothesis for the binding mode of HERG channel blockers.
    Choe H; Nah KH; Lee SN; Lee HS; Lee HS; Jo SH; Leem CH; Jang YJ
    Biochem Biophys Res Commun; 2006 May; 344(1):72-8. PubMed ID: 16616004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human ether-a-go-go-related gene channel blockers and its structural analysis for drug design.
    Narayana Moorthy NS; Ramos MJ; Fernandes PA
    Curr Drug Targets; 2013 Jan; 14(1):102-13. PubMed ID: 23061466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel structure-based virtual screening model for the hERG channel blockers.
    Du L; Li M; You Q; Xia L
    Biochem Biophys Res Commun; 2007 Apr; 355(4):889-94. PubMed ID: 17331468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of van der Waals surface area properties for human ether-a-go-go-related gene blocking activity: computational study on structurally diverse compounds.
    Moorthy NS; Ramos MJ; Fernandes PA
    SAR QSAR Environ Res; 2012 Jul; 23(5-6):521-36. PubMed ID: 22452318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacophore modeling for hERG channel facilitation.
    Yamakawa Y; Furutani K; Inanobe A; Ohno Y; Kurachi Y
    Biochem Biophys Res Commun; 2012 Feb; 418(1):161-6. PubMed ID: 22244872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
    Durdagi S; Duff HJ; Noskov SY
    J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A composite model for HERG blockade.
    Kramer C; Beck B; Kriegl JM; Clark T
    ChemMedChem; 2008 Feb; 3(2):254-65. PubMed ID: 18061919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards in silico identification of the human ether-a-go-go-related gene channel blockers: discriminative vs. generative classification models.
    Kireeva N; Kuznetsov SL; Bykov AA; Tsivadze AY
    SAR QSAR Environ Res; 2013; 24(2):103-17. PubMed ID: 23152964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
    Zachariae U; Giordanetto F; Leach AG
    J Med Chem; 2009 Jul; 52(14):4266-76. PubMed ID: 19534531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico prediction of hERG inhibition.
    Jing Y; Easter A; Peters D; Kim N; Enyedy IJ
    Future Med Chem; 2015; 7(5):571-86. PubMed ID: 25921399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similarity-based SIBAR descriptors for classification of chemically diverse hERG blockers.
    Thai KM; Ecker GF
    Mol Divers; 2009 Aug; 13(3):321-36. PubMed ID: 19219559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interactions between hERG potassium channel and blockers.
    Du L; Li M; You Q
    Curr Top Med Chem; 2009; 9(4):330-8. PubMed ID: 19442204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive models for HERG channel blockers: ligand-based and structure-based approaches.
    Thai KM; Ecker GF
    Curr Med Chem; 2007; 14(28):3003-26. PubMed ID: 18220737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hERG potassium channel as a therapeutic target.
    Witchel HJ
    Expert Opin Ther Targets; 2007 Mar; 11(3):321-36. PubMed ID: 17298291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An automated docking protocol for hERG channel blockers.
    Di Martino GP; Masetti M; Ceccarini L; Cavalli A; Recanatini M
    J Chem Inf Model; 2013 Jan; 53(1):159-75. PubMed ID: 23259741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive in silico modeling for hERG channel blockers.
    Aronov AM
    Drug Discov Today; 2005 Jan; 10(2):149-55. PubMed ID: 15718164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuning out of hERG.
    Aronov AM
    Curr Opin Drug Discov Devel; 2008 Jan; 11(1):128-40. PubMed ID: 18175275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.